I think companies should be required to disclose some information to the public, but this depends on the type of information. For example, information about a product’s complete ingredient list, cautions, adverse effects, etc. is crucial to disclose to the public. However, I don’t think that every detail needs to be disclosed, such as the processes that were selected to manufacture the product. However, for the information that should be disclosed, it is important to release everything to the public, even if it may damage the company’s reputation. Disclosing information that might damage a company’s reputation might actually benefit them in the long run because they will develop a trusting relationship with their customers by being open about their mistakes. When customers are deciding between two competing products, they are more likely to trust the company that is open about their mistakes and challenges. Does anyone know of any previous situations where a company benefited and grew from disclosing their mistakes?

It's hard to tell how much information should disclose in the long term. But I believe the insert package, for example, has included everything the public should know. The part that is hard to define is the manufacturing process or communication record inside the company. It's risky because disclosing the manufacturing record would result in a reduction in the product value. However, it's also advantageous for the regulatory process and advertising to the clients. Therefore, disclosing the information enough to earn the client's trust and protect the product's patent is significant for a company to deal with.

This is a complex ethics question that doesn't have a simple answer. On one hand, transparency is important for building trust with stakeholders and ensuring accountability; on the other, there may be situations where disclosing certain information could harm the organization or its stakeholders. Ultimately, the decision to disclose information should be made on a case-by-case basis, weighing the potential benefits and risks of disclosure. In the case of medical devices; some may say that our industry requires the most transparency. These are items that are being used in medicine. Just as doctors take an oath; we must also be as noble in our pursuit of more and more advancements in medical device science.

I would like to bring in some nuanced perspectives from what has been said so far. I agree that there are certain things that should be completely disclosed to the public; however, I think the timing of the transparency matters more than the transparency itself. When the company discloses this information can make a huge difference in how impactful the transparency is in saving the company or harming it. Disclosing information early can cause panic in the public when the information is of a concerning nature, but also disclosing information too late can damage the trust the public has in you, since it will look like you withheld information from them. So, ensuring that whatever information the company discloses is accurate, would not cause panic, and is disclosed at the correct time, is essential to ensuring that the company maintains its customers and respect. 

I also want to touch on over-disclosure, as sometimes this can be harmful in medical devices. Too much technical detail can confuse the patients and even the clinicians, since giving engineering terms to those who are well-versed in medicine or not well-versed in any of those terms would lead to confusion and loss of customers to other, better communicated companies. Additionally, I wanted to talk about how legal vs. ethical disclosure is not the same. Some companies may meet the regulatory requirements and withhold some information from the public, which is not ethical. I think legal disclosure is the minimum standard, but to be ethical, a company has to release all the fine print in a way that is digestible and understandable to the public to increase public trust and also prevent any harm. 

Who do you think companies should prioritize when disclosing information to the public in medical devices? Should they prioritize patients, clinicians, or regulators? Additionally, how do you think companies should handle disclosure when they are uncertain about the full extent of an issue?

The debate over mandatory disclosure mostly originates from the tension between public accountability and organizational survival. On one hand, transparency is key to maintaining societal expectations; for markets to be efficient and for consumers to remain safe, organizations must disclose any material information. When a company hides environmental hazards or financial instability to protect its bottom line, it isn't just managing its reputation, it is shifting the risk onto an uninformed public.

However, a requirement to disclose all information is impractical. Radical transparency can jeopardize proprietary trade secrets and expose internal deliberations that, while harmless, could be easily misinterpreted or exaggerated by the media. This chilling effect could stifle innovation and prevent honest internal problem-solving.

Ultimately, the standard should be a harm-based hierarchy. While organizations should have the right to protect their proprietary knowledge and methods, that right ends when public safety, human rights, or market integrity begin to come into question. If the information is vital to the common good, the organization’s bottom line should never be the priority.

Do you think we can trust organizations to decide what is "material," or do we need more aggressive third-party auditing to keep them honest?

The points raised about timing and legal versus ethical disclosure really stand out to me as I think Dev's framing is spot on: meeting regulatory minimums is not the same as being ethical, and in medical devices especially, that gap can have real consequences for patients who are making life-altering decisions based on incomplete information. Building on cra24's harm-based hierarchy idea, I'd argue the determining factor should be whether withholding the information transfers risk onto someone who never consented to bear it, because at that point, it stops being a business decision and becomes an ethical violation regardless of legality. On the over-disclosure concern, I think the solution isn't less transparency but better communication design. Companies have a responsibility to translate complex technical findings into accessible language for each audience, whether that's a patient, clinician, or regulator, rather than using complexity as a shield. To Dev's question about who should be prioritized, I'd say patients first, since they carry the most personal risk and have the least institutional power to demand answers. As for handling uncertainty, companies should disclose what they know, be explicit about what they don't, and communicate a clear timeline for follow-up. Ambiguity acknowledged openly is far less damaging than silence that later looks like concealment.